Vir Biotechnology
143 hedge funds and large institutions have $2.11B invested in Vir Biotechnology in 2020 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 55 increasing their positions, 25 reducing their positions, and 21 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 25
114% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 21
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
20% more funds holding
Funds holding: 119 → 143 (+24)
6.82% more ownership
Funds ownership: 55.14% → 61.95% (+6.8%)
12% less capital invested
Capital invested by funds: $2.41B → $2.11B (-$293M)
23% less call options, than puts
Call options by funds: $10.9M | Put options by funds: $14.3M
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$65.2M |
| 2 |
BlackRock
New York
|
+$44.7M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$28.8M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$11.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.9M |
Top Sellers
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$6.85M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$3.84M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.11M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.95M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$2.21M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CL
151
CSS LLC
Chicago,
Illinois
| – | -$47K | -1,364 | Closed |
|
152
Simplex Trading
Chicago,
Illinois
| – | -$37.1K | -1,141 | Closed |
|
|
MAM
153
Meeder Asset Management
Dublin,
Ohio
| – | -$19K | -560 | Closed |
|
154
Group One Trading
Chicago,
Illinois
| – | -$12K | -368 | Closed |
|
|
ASN
155
Advisory Services Network
Atlanta,
Georgia
| – | -$12K | -343 | Closed |
|
156
Lazard Asset Management
New York
| – | -$8K | -242 | Closed |
|
157
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
| – | -$8K | -220 | Closed |
|
|
GWM
158
Geneos Wealth Management
Englewood,
Colorado
| – | -$3K | -100 | Closed |
|
|
FCH
159
Freestone Capital Holdings
Seattle,
Washington
| – | -$1.72K | -50 | Closed |
|
|
FHA
160
Flagship Harbor Advisors
Boston,
Massachusetts
| – | -$1K | -32 | Closed |
|
161
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$1K | -26 | Closed |
|
162
Fidelity Investments
Boston,
Massachusetts
| – | +$195 | +6 | New |
|
VIR Hedge Fund Activity: Q4 2020 in Review
143 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q4 2020, worth a combined $2.11B — down 12% from $2.41B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new VIR positions and 21 closed out — a net gain of 24 holders — while 55 added to existing stakes and 25 trimmed.
The largest buyer was State Street, adding an estimated $65.2M. The largest seller was Clough Capital Partners, exiting entirely with an estimated $6.85M sold.
- 143 institutional investors held Vir Biotechnology (VIR) as of Q4 2020, up from 119 in Q3 2020.
- Funds reported $2.11B of Vir Biotechnology stock for Q4 2020, down 12% quarter-over-quarter.
- 45 funds opened new Vir Biotechnology positions in Q4 2020 and 21 closed out, a net change of +24 holders.
- The largest Vir Biotechnology buyer in Q4 2020 was State Street, an estimated $65.2M added.
- The largest Vir Biotechnology seller in Q4 2020 was Clough Capital Partners, an estimated $6.85M sold.
Based on aggregated 13F filings for Q4 2020.